Literature DB >> 31077345

Exploring mitochondrial cholesterol signalling for therapeutic intervention in neurological conditions.

Radha Desai1, Michelangelo Campanella1,2.   

Abstract

The pharmacological targeting of cholesterol levels continues to generate interest due to the undoubted success of therapeutic agents, such as statins, in extending life expectancy by modifying the prognosis of diseases associated with the impairment of lipid metabolism. Advances in our understanding of mitochondrial dysfunction in chronic age-related diseases of the brain have disclosed an emerging role for mitochondrial cholesterol in their pathophysiology, thus delineating an opportunity to provide mechanistic insights and explore strategies of intervention. This review draws attention to novel signalling mechanisms in conditions linked with impaired metabolism associated with impaired handling of cholesterol and its oxidized forms (oxysterols) by mitochondria. By emphasizing the role of mitochondrial cholesterol in neurological diseases, we here call for novel approaches and new means of assessment. LINKED ARTICLES: This article is part of a themed section on Mitochondrial Pharmacology: Featured Mechanisms and Approaches for Therapy Translation. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v176.22/issuetoc.
© 2019 The British Pharmacological Society.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31077345      PMCID: PMC6887905          DOI: 10.1111/bph.14697

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  71 in total

Review 1.  Cholesterol and related sterols autoxidation.

Authors:  Chiara Zerbinati; Luigi Iuliano
Journal:  Free Radic Biol Med       Date:  2017-04-18       Impact factor: 7.376

2.  Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials.

Authors:  Jordan Fulcher; Rachel O'Connell; Merryn Voysey; Jonathan Emberson; Lisa Blackwell; Borislava Mihaylova; John Simes; Rory Collins; Adrienne Kirby; Helen Colhoun; Eugene Braunwald; John La Rosa; T R Pedersen; Andrew Tonkin; Barry Davis; Peter Sleight; Maria Grazia Franzosi; Colin Baigent; Anthony Keech
Journal:  Lancet       Date:  2015-01-09       Impact factor: 79.321

3.  Mitochondrial cholesterol loading exacerbates amyloid beta peptide-induced inflammation and neurotoxicity.

Authors:  Anna Fernández; Laura Llacuna; José C Fernández-Checa; Anna Colell
Journal:  J Neurosci       Date:  2009-05-20       Impact factor: 6.167

Review 4.  Mitochondria: Targeting mitochondrial reactive oxygen species with mitochondriotropic polyphenolic-based antioxidants.

Authors:  José Teixeira; Cláudia M Deus; Fernanda Borges; Paulo J Oliveira
Journal:  Int J Biochem Cell Biol       Date:  2018-02-14       Impact factor: 5.085

Review 5.  Regulation of Mitochondrial, Cellular, and Organismal Functions by TSPO.

Authors:  Moshe Gavish; Leo Veenman
Journal:  Adv Pharmacol       Date:  2017-11-13

6.  A Metadata Analysis of Oxidative Stress Etiology in Preclinical Amyotrophic Lateral Sclerosis: Benefits of Antioxidant Therapy.

Authors:  Leila Bond; Kamren Bernhardt; Priyank Madria; Katherine Sorrentino; Hailee Scelsi; Cassie S Mitchell
Journal:  Front Neurosci       Date:  2018-01-24       Impact factor: 4.677

7.  Neuroprotective effects of the mitochondria-targeted antioxidant MitoQ in a model of inherited amyotrophic lateral sclerosis.

Authors:  Ernesto Miquel; Adriana Cassina; Laura Martínez-Palma; José M Souza; Carmen Bolatto; Sebastián Rodríguez-Bottero; Angela Logan; Robin A J Smith; Michael P Murphy; Luis Barbeito; Rafael Radi; Patricia Cassina
Journal:  Free Radic Biol Med       Date:  2014-02-26       Impact factor: 7.376

8.  Targeting translocator protein (18 kDa) (TSPO) dampens pro-inflammatory microglia reactivity in the retina and protects from degeneration.

Authors:  Rebecca Scholz; Albert Caramoy; Mohajeet B Bhuckory; Khalid Rashid; Mei Chen; Heping Xu; Christian Grimm; Thomas Langmann
Journal:  J Neuroinflammation       Date:  2015-11-02       Impact factor: 8.322

9.  THE CONCISE GUIDE TO PHARMACOLOGY 2017/18: Nuclear hormone receptors.

Authors:  Stephen Ph Alexander; John A Cidlowski; Eamonn Kelly; Neil V Marrion; John A Peters; Elena Faccenda; Simon D Harding; Adam J Pawson; Joanna L Sharman; Christopher Southan; Jamie A Davies
Journal:  Br J Pharmacol       Date:  2017-12       Impact factor: 8.739

Review 10.  The genetic architecture of mitochondrial dysfunction in Parkinson's disease.

Authors:  S B Larsen; Z Hanss; R Krüger
Journal:  Cell Tissue Res       Date:  2018-01-25       Impact factor: 5.249

View more
  4 in total

1.  Mitochondrial pharmacology: featured mechanisms and approaches for therapy translation.

Authors:  Xin Wang; Gina Galli; Michelangelo Campanella
Journal:  Br J Pharmacol       Date:  2019-11       Impact factor: 8.739

2.  Pharmacogenomics of in vitro response of the NCI-60 cancer cell line panel to Indian natural products.

Authors:  Hari Sankaran; Simarjeet Negi; Lisa M McShane; Yingdong Zhao; Julia Krushkal
Journal:  BMC Cancer       Date:  2022-05-07       Impact factor: 4.638

Review 3.  Mitochondrial Targeting Involving Cholesterol-Rich Lipid Rafts in the Mechanism of Action of the Antitumor Ether Lipid and Alkylphospholipid Analog Edelfosine.

Authors:  Faustino Mollinedo; Consuelo Gajate
Journal:  Pharmaceutics       Date:  2021-05-20       Impact factor: 6.321

4.  Knock-Out of ACBD3 Leads to Dispersed Golgi Structure, but Unaffected Mitochondrial Functions in HEK293 and HeLa Cells.

Authors:  Tereza Daňhelovská; Lucie Zdražilová; Hana Štufková; Marie Vanišová; Nikol Volfová; Jana Křížová; Ondřej Kuda; Jana Sládková; Markéta Tesařová
Journal:  Int J Mol Sci       Date:  2021-07-06       Impact factor: 5.923

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.